Description
Phase
Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.Inclusion and Exclusion Criteria
Please contact the trial administrator to learn more about the eligibility criteria for this trial. Please use the contact form on the right side.
Sites
-
California
- City of Hope: Duarte, Duarte, California, 91010
- UCLA: Jonsson Comprehensive Cancer Center, Los Angeles, California, 90095
- USC: Norris Comprehensive Cancer Center, Los Angeles, California, 90089
- City of Hope: Antelope Valley, Lancaster, California, 93534
-
New Mexico
- University of New Mexico Cancer Center: Albuquerque, Albuquerque, New Mexico, 87131
- University of New Mexico Cancer Center: Las Cruces, Las Cruces, New Mexico, 88011
-
Nebraska
- Nebraska Cancer Specialists, Omaha, Nebraska, 68114
-
Missouri
- Siteman Cancer Center, St. Louis, Missouri, 63110
-
Wisconsin
- Froedtert & Medical College of Wisconsin, Milwaukee, Wisconsin, 53226
-
Alabama
- University of Alabama Hematology Oncology Clinic at Medical West, Birmingham, Alabama, 35294
-
Indiana
- Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, 46202
- IU Health Central Indiana Cancer Centers, Indianapolis, Indiana, 46219
- IU Health Goshen Hospital, Goshen, Indiana, 46527
- IU Health at Ball Memorial Hospital, Muncie, Indiana, 47303
Powered by
SC CTSI